|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:clinicalTrials.gov_Identifier
|
gptkb:NCT00530894
|
|
gptkbp:controls
|
standard therapy
surgical aortic valve replacement
|
|
gptkbp:enrollment
|
over 1000 patients
|
|
gptkbp:focus
|
severe aortic stenosis
transcatheter aortic valve replacement
|
|
gptkbp:fullName
|
gptkb:Placement_of_Aortic_Transcatheter_Valves_(PARTNER)_trial
|
|
gptkbp:impact
|
established TAVR as standard of care for high-risk patients
|
|
gptkbp:intervention
|
gptkb:SAPIEN_transcatheter_heart_valve
|
|
gptkbp:location
|
gptkb:Canada
gptkb:Germany
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:period
|
Phase 3
|
|
gptkbp:principalInvestigator
|
gptkb:Craig_R._Smith
gptkb:Martin_B._Leon
|
|
gptkbp:publishedIn
|
gptkb:N_Engl_J_Med._2010;363:1597-1607
|
|
gptkbp:relatedTo
|
gptkb:PARTNER_2_trial
gptkb:PARTNER_3_trial
|
|
gptkbp:result
|
TAVR superior to standard therapy in inoperable patients
TAVR non-inferior to surgery in high-risk patients
all-cause mortality
|
|
gptkbp:sponsor
|
gptkb:Edwards_Lifesciences
|
|
gptkbp:startDate
|
2007
|
|
gptkbp:bfsParent
|
gptkb:SAPIEN_transcatheter_heart_valve
|
|
gptkbp:bfsLayer
|
7
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
PARTNER trial
|